Skip to content

Study · Not a test of the peptide alone · 2019

1 result

A method for confirming CJC-1295 abuse in equine plasma samples by LC-MS/MS.

Timms M, Ganio K, Steel R

Drug testing and analysis8 May 2019Cited by 2 (Europe PMC)

PMID30938069 (opens in a new tab)DOI10.1002/dta.2599 (opens in a new tab)PepBankPUB-30938069
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking CJC-1295 (with DAC).

  1. 01LabNot a test of CJC-1295 (with DAC) aloneOther designOther

    An LC-MS/MS method with immuno-affinity capture and tryptic digestion identified CJC‑1295 in equine plasma down to 180 pg/mL in 1 mL.

    In plain wordsIn lab tests, a mass spectrometry method confirmed CJC‑1295 in horse plasma at very low levels.

    Peptide
    CJC-1295 (with DAC)
    Outcome
    Not applicableLC-MS/MS confirmation limit in equine plasma
    Study

    horsen: not reported in source

    Equine plasma
    Outcome group
    Analytical methods and detection · Pharmacology

    Measurements

    Detection limit
    180 pg/mL
    1 mL equine plasma, LC-MS/MS

    Source sentences

    Summary
    Here we demonstrate the confirmation of CJC-1295 in equine plasma by LC-MS/MS after immuno-affinity capture and tryptic digestion. Using this method, CJC-1295 was identified down to concentrations as low as 180 pg/mL in 1 mL of equine plasma.

    In this study, CJC-1295 (with DAC) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking CJC-1295 (with DAC).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.